Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21891951 | 0.84 | HDAC4 (0.44) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL19115944 | 0.79 | HDAC2 (0.47) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL9004436 | 0.79 | HDAC2 (0.50) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL9004443 | 0.73 | HDAC2 (0.52) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL18857348 | 0.73 | HDAC4 (0.44) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL14606179 | 0.69 | HDAC2 (0.55) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL2559392 | 0.68 | — | — | |
| SCHEMBL720598 | 0.68 | — | — | |
| SCHEMBL2774579 | 0.67 | HDAC2 (0.60) | HDAC4HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL6965531 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HDAC4 2091/4885HDAC2 2773/4885HDAC8 947/4885 |
| US-20200385364-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HDAC4 2237/4885HDAC2 2739/4885HDAC8 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.